摘要: Biomarker discovery is one of the newly emerging innovations in diagnosis and treatment cancer many other diseases. Many research groups large pharmaceutical companies are actively engaged searching for novel biomarkers malignant diseases, which will make molecular analysis monitoring disease possible. technologies, including genomics, proteomics metabolomics, used to identify biomarkers. Among types cancers lung cancer--owing difficulty diagnosing at an early stage--urgently needs development as tools detection, well monitoring. Several DNA protein have been identified, but most previously discovered correlated with general process carcinogenesis immune responses. Therefore, these found cancers, thus not specific cancer. biomarker still needed, among possible samples, blood thought be ideal this it can collected easily a minimally invasive manner. studies now being conducted find blood. With advances methods technology, together considerable efforts diagnostic biomarkers, candidates discovered; leading diagnosis, efficient cancers.
expert-reviews.com参考文章(96)
D A Gadkari, B H Shaikh, IgM antibody capture ELISA in the diagnosis of Japanese encephalitis, West Nile & dengue virus infections. Indian Journal of Medical Research. ,vol. 80, pp. 613- 619 ,(1984)
Robert Perkel, Christopher Haines, Lauren G. Collins, Robert E. Enck, Lung Cancer: Diagnosis and Management American Family Physician. ,vol. 75, pp. 56- 63 ,(2007)
Domont Gb, Paschoal Me, Kawamura Mt, Carvalho Mda G, Junqueira M, Maciel Cm, Duarte Rl, Differential proteomic serum pattern of low molecular weight proteins expressed by adenocarcinoma lung cancer patients. Journal of Experimental Therapeutics and Oncology. ,vol. 5, pp. 31- 38 ,(2005)
Wright Gl, Dalmasso Ea, Fung Et, Proteomic strategies for biomarker identification: progress and challenges. Current Opinion in Molecular Therapeutics. ,vol. 2, pp. 643- ,(2000)
Zofia Stasik, Jan Kulpa, Ewa Wojcik, Andrzej Radkowski, Leszek Kolodziejski, CYFRA 21-1, TPA-M, TPS, SCC-Ag and CEA in patients with squamous cell lung cancer and in chemical industry workers as a reference group. Anticancer Research. ,vol. 20, pp. 5035- 5040 ,(2000)
John M. S. Bartlett, David Stirling, A short history of the polymerase chain reaction. Methods of Molecular Biology. ,vol. 226, pp. 3- 6 ,(2003) , 10.1385/1-59259-384-4:3
Wei-Min Gao, Rork Kuick, Randal P Orchekowski, David E Misek, Ji Qiu, Alissa K Greenberg, William N Rom, Dean E Brenner, Gilbert S Omenn, Brian B Haab, Samir M Hanash, Distinctive serum protein profiles involving abundant proteins in lung cancer patients based upon antibody microarray analysis BMC Cancer. ,vol. 5, pp. 110- 110 ,(2005) , 10.1186/1471-2407-5-110
Joachim Schneider, Tumor markers in detection of lung cancer. Advances in Clinical Chemistry. ,vol. 42, pp. 1- 41 ,(2006) , 10.1016/S0065-2423(06)42001-1
Takehiko Sasazuki, Hideki Yokoyama, Teruyoshi Ishida, Takashi Inoue, Keizo Sugimachi, Kenji Sugio, ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. Cancer Research. ,vol. 52, pp. 2903- 2906 ,(1992)
Sjoerd Rodenhuis, Robert J. C. Slebos, Clinical significance of ras oncogene activation in human lung cancer. Cancer Research. ,vol. 52, pp. 2665- 2669 ,(1992)